- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 00:46 | Dreem Health Launches 3 Partnerships to Address Sleep Disorders | ||
| Di | With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test | ||
| Di | Healthcare Price Transparency is Not Enough | ||
| Di | On-Demand Relief: What IV Therapy Company Offers the Fastest Service? | ||
| Di | Evaluating the Complexities of the Digital Operating Room | ||
| Di | Without Clear Strategy, CMS' $50B Rural Hospital Fund Risks Falling Short | ||
| Mo | Report: Member Satisfaction in MA Insurers Is Dropping Due to Lack of Trust | ||
| Mo | FDA Suspends Valneva Vaccine's License Following New Reports of Adverse Events | ||
| Mo | The Top-Rated Assistive Devices for Children With Sensory Processing Disorders | ||
| Mo | Supporting the Whole Patient: The Psychological Value of Scalp Cooling in Breast Cancer Treatment | ||
| Mo | Regulatory Shift Paves Way for AI-Driven Heart Disease Diagnosis | ||
| Mo | The Critical Link: How Supporting Nurse Managers Can Help Nurses - And Improve Healthcare | ||
| Mo | First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen? | ||
| Mo | Insurers are Pulling Back on MA. How Does this Affect Patients? | ||
| So | AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions and Costs | ||
| So | After Wegovy's Historic MASH Approval, What's Next? | ||
| So | Secretary Kennedy's Pride and Prejudice | ||
| Fr | In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug | ||
| Fr | 3 Announcements You Don't Want to Miss from Epic's Annual Meeting | ||
| Fr | The Integration Opportunity: A Blueprint for Reliable Device Data | ||
| Fr | Home Sweet Healthcare: Why the Best Care Setting Is Outside the Clinic | ||
| Fr | MedCity Pivot Podcast: Clinical Documentation Improvement With Smarter Technologies | ||
| Fr | Array Behavioral Care Introduces Model for Standardizing Mental Health Treatment | ||
| Do | Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition | ||
| Do | Could Small Cash Prizes Motivate People to Be Healthier? Investors Say Yes |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .